Somapacitan (INN) (brand name Somavaratan) is an injectable gonadotropin-releasing hormone (GnRH) agonist developed to treat adult growth hormone deficiency. It is a long-acting, depot formulation of a GnRH agonist, which is injected once monthly. Somapacitan works by reducing the production of growth hormone, which helps to regulate a person’s metabolism, energy levels, and body composition. This drug has been approved by the US Food and Drug Administration (FDA) and is currently marketed in the United States. Studies have shown that Somapacitan is safe and effective in treating adult growth hormone deficiency.
Somapacitan is a human growth hormone (hGH) medication sold under the brand name Sogroya. It is the first FDA-approved once-a-week hGH therapy for adults with growth hormone deficiency (GHD) . Unlike other FDA-approved hGH formulations for adults, which require daily injections, Somapacitan is administered subcutaneously (under the skin) only once a week.
Here's a summary of Somapacitan:
- Type of drug: Human growth hormone analog
- Brand name: Sogroya
- Uses: Replacement of endogenous growth hormone in adults with GHD
- Dosage form: Subcutaneous injection (5 mg, 10 mg, or 15 mg)
- Approval date: August 28, 2020 (FDA), March 2021 (European Union)
Growth hormone deficiency (GHD) is a condition that occurs when the pituitary gland doesn't produce enough growth hormone. Growth hormone is a hormone that helps regulate many functions in the body, including growth, bone development, metabolism, and body composition.